Literature DB >> 7935401

Functional complementation of major histocompatibility complex class II regulatory mutants by the purified X-box-binding protein RFX.

B Durand1, M Kobr, W Reith, B Mach.   

Abstract

Major histocompatibility complex (MHC) class II deficiency, or bare lymphocyte syndrome (BLS), is a disease of gene regulation. Patients with BLS have been classified into at least three complementation groups (A, B, and C) believed to correspond to three distinct MHC class II regulatory genes. The elucidation of the molecular basis for this disease will thus clarify the mechanisms controlling the complex regulation of MHC class II genes. Complementation groups B and C are characterized by a lack of binding of RFX, a nuclear protein that normally binds specifically to the X box cis-acting element present in the promoters of all MHC class II genes. We have now purified RFX to near homogeneity by affinity chromatography. Using an in vitro transcription system based on the HLA-DRA promoter, we show here that extracts from RFX-deficient cells from patients with BLS (BLS cells) in groups B and C, which are transcriptionally inactive in this assay, can be complemented to full transcriptional activity by the purified RFX. As expected, purified RFX also restores a completely normal pattern of X box-binding complexes in these mutant extracts. This provides the first direct functional evidence that RFX is an activator of MHC class II gene transcription and that its absence is indeed responsible for the regulatory defect in MHC class II gene expression in patients with BLS.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7935401      PMCID: PMC359214          DOI: 10.1128/mcb.14.10.6839-6847.1994

Source DB:  PubMed          Journal:  Mol Cell Biol        ISSN: 0270-7306            Impact factor:   4.272


  39 in total

1.  The DNA-binding defect observed in major histocompatibility complex class II regulatory mutants concerns only one member of a family of complexes binding to the X boxes of class II promoters.

Authors:  C Herrero Sanchez; W Reith; P Silacci; B Mach
Journal:  Mol Cell Biol       Date:  1992-09       Impact factor: 4.272

Review 2.  Sequences and factors: a guide to MHC class-II transcription.

Authors:  L H Glimcher; C J Kara
Journal:  Annu Rev Immunol       Date:  1992       Impact factor: 28.527

3.  Factors involved in specific transcription by human RNA polymerase II: analysis by a rapid and quantitative in vitro assay.

Authors:  M Sawadogo; R G Roeder
Journal:  Proc Natl Acad Sci U S A       Date:  1985-07       Impact factor: 11.205

4.  Complementation cloning of an MHC class II transactivator mutated in hereditary MHC class II deficiency (or bare lymphocyte syndrome).

Authors:  V Steimle; L A Otten; M Zufferey; B Mach
Journal:  Cell       Date:  1993-10-08       Impact factor: 41.582

5.  Function of major histocompatibility complex class II promoters requires cooperative binding between factors RFX and NF-Y.

Authors:  W Reith; C A Siegrist; B Durand; E Barras; B Mach
Journal:  Proc Natl Acad Sci U S A       Date:  1994-01-18       Impact factor: 11.205

6.  Antisense oligonucleotides specific for regulatory factor RFX-1 inhibit inducible but not constitutive expression of all major histocompatibility complex class II genes.

Authors:  C A Siegrist; B Mach
Journal:  Eur J Immunol       Date:  1993-11       Impact factor: 5.532

Review 7.  Regulation of MHC gene expression.

Authors:  J P Ting; A S Baldwin
Journal:  Curr Opin Immunol       Date:  1993-02       Impact factor: 7.486

8.  RFX1 is identical to enhancer factor C and functions as a transactivator of the hepatitis B virus enhancer.

Authors:  C A Siegrist; B Durand; P Emery; E David; P Hearing; B Mach; W Reith
Journal:  Mol Cell Biol       Date:  1993-10       Impact factor: 4.272

9.  RFX1, a transactivator of hepatitis B virus enhancer I, belongs to a novel family of homodimeric and heterodimeric DNA-binding proteins.

Authors:  W Reith; C Ucla; E Barras; A Gaud; B Durand; C Herrero-Sanchez; M Kobr; B Mach
Journal:  Mol Cell Biol       Date:  1994-02       Impact factor: 4.272

10.  Human B cell variants immunoselected against a single Ia antigen subset have lost expression of several Ia antigen subsets.

Authors:  R S Accolla
Journal:  J Exp Med       Date:  1983-03-01       Impact factor: 14.307

View more
  28 in total

1.  CIITA is a transcriptional coactivator that is recruited to MHC class II promoters by multiple synergistic interactions with an enhanceosome complex.

Authors:  K Masternak; A Muhlethaler-Mottet; J Villard; M Zufferey; V Steimle; W Reith
Journal:  Genes Dev       Date:  2000-05-01       Impact factor: 11.361

2.  Self-association of CIITA and its transactivation potential.

Authors:  T J Sisk; S Roys; C H Chang
Journal:  Mol Cell Biol       Date:  2001-08       Impact factor: 4.272

Review 3.  Impaired regulation of HLA-DR expression in human immunodeficiency virus-infected monocytes.

Authors:  Ling Shao; Kirk Sperber
Journal:  Clin Diagn Lab Immunol       Date:  2002-07

Review 4.  Novel mechanisms of class II major histocompatibility complex gene regulation.

Authors:  Michael Radosevich; Santa Jeremy Ono
Journal:  Immunol Res       Date:  2003       Impact factor: 2.829

5.  Complex architecture of major histocompatibility complex class II promoters: reiterated motifs and conserved protein-protein interactions.

Authors:  N Jabrane-Ferrat; J D Fontes; J M Boss; B M Peterlin
Journal:  Mol Cell Biol       Date:  1996-09       Impact factor: 4.272

6.  Specific complex formation between the type II bare lymphocyte syndrome-associated transactivators CIITA and RFX5.

Authors:  T Scholl; S K Mahanta; J L Strominger
Journal:  Proc Natl Acad Sci U S A       Date:  1997-06-10       Impact factor: 11.205

7.  Deficient antigen-presenting cell function in multiple genetic complementation groups of type II bare lymphocyte syndrome.

Authors:  S Kovats; G T Nepom; M Coleman; B Nepom; W W Kwok; J S Blum
Journal:  J Clin Invest       Date:  1995-07       Impact factor: 14.808

8.  The RAG cell line defines a new complementation group of MHC class II deficiency.

Authors:  A Lennon; C Ottone; A Peijnenburg; C Hamon-Benais; F Colland; S Gobin; P van den Elsen; M Fellous; R Bono; C Alcaïde-Loridan
Journal:  Immunogenetics       Date:  1996       Impact factor: 2.846

9.  Formation of the RFX gene regulatory complex induces folding of the interaction domain of RFXAP.

Authors:  LaTese Briggs; Kholiswa Laird; Jeremy M Boss; Colin W Garvie
Journal:  Proteins       Date:  2009-08-15

10.  Splicing defect in RFXANK results in a moderate combined immunodeficiency and long-duration clinical course.

Authors:  Thomas Prod'homme; Benjamin Dekel; Giovanna Barbieri; Barbara Lisowska-Grospierre; Rina Katz; Dominique Charron; Catherine Alcaide-Loridan; Shimon Pollack
Journal:  Immunogenetics       Date:  2003-10-22       Impact factor: 2.846

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.